Prosecution Insights
Last updated: November 04, 2026
Application No. 18/570,499

Collagen Type XX Assay

Non-Final OA §112
Filed
Dec 14, 2023
Priority
Jun 18, 2021 — GB 2108802.6 +1 more
Examiner
VOLKOV, ALEXANDER ALEXANDROVIC
Art Unit
1677
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nordic Bioscience A/S
OA Round
1 (Non-Final)
30%
Grant Probability
At Risk
1-2
OA Rounds
1y 2m
Est. Remaining
51%
With Interview

Examiner Intelligence

Grants only 30% of cases
30%
Career Allowance Rate
28 granted / 95 resolved
-30.5% vs TC avg
Strong +22% interview lift
Without
With
+21.5%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
35 currently pending
Career history
137
Total Applications
across all art units

Statute-Specific Performance

§101
8.9%
-31.1% vs TC avg
§103
37.8%
-2.2% vs TC avg
§102
12.3%
-27.7% vs TC avg
§112
31.8%
-8.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 95 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-17 are examined herein. Claim Objections Claim 1 is objected to because of the following informalities: Claim 1 recites “The method of claim 1, wherein the method further comprises: iii) correlating said amount”. Should be “The method of claim 1, wherein the method further comprises: correlating said amount”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL. —The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 10-17 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 10 and 14 recite a monoclonal antibody by its binding properties for peptide of SEQ ID NO:1. An original claim may lack written description support when a broad genus claim is presented but the disclosure only describes a narrow species with no evidence that the genus is contemplated. See Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1349-50 (Fed. Cir. 2010) (en banc) (MPEP §2163.03.V). “[T]he disclosure must adequately reflect the structural diversity of the claimed genus, either through the disclosure of sufficient species that are "representative of the full variety or scope of the genus," or by the establishment of "a reasonable structure-function correlation." (MPEP § 2163.II.A). A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. See AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 1285, 1300, 111 USPQ2d 1780, 1790 (Fed. Cir. 2014) (Claims directed to a functionally defined genus of antibodies were not supported by a disclosure that "only describe[d] one type of structurally similar antibodies" that "are not representative of the full variety or scope of the genus.") (MPEP § 2163). In the instant case, claims 10 and 14 are directed to any antibody with recited properties. Additionally, the antibody is claimed not by its structure but by its binding specificity. The specification discloses only one antibody with claimed binding properties and its heavy chain sequence (pg. 12) and light chain sequence (pg. 13). The teachings of the instant specification disclose only one antibody and do not demonstrate that Applicant had knowledge of the structural features common to members of the entire genus of antibodies. The teachings of the instant specification are insufficient to establish possession of the breadth of antibodies required to practice the claimed invention consistent with the written description requirement of 35 U.S.C. § 112(a). Therefore, claims 10-17 are rejected under 35 U.S.C. 112(a) for failure to describe a sufficient number of different antibodies with claimed binding specificity. Subject Matter Free of the Prior Art Claims 1-9 are allowable. Claims 10-17 are free of the prior art. The prior art neither teaches nor suggests a monoclonal antibody that specifically binds to a C-terminus amino acid sequence QGASTQGLWE; does not specifically bind to an elongated version of said C-terminus amino acid sequence which is QGASTQGLWES; and does not specifically bind to a truncated version of said C-terminus amino acid sequence which is QGASTQGLW. The closest prior art: Xu et al. (IDS; J Transl Med. 2019 Sep 14;17(1)). The reference teaches the role of collagen in cancer but fails to teach an antibody with specificity to SEQ ID NO:1. Gorlov et al. (IDS; BMC Med Genomics. 2009 Aug 4;2:48) teach genes involved in prostate cancer (pg. 4, col. 2, par. 3) but fail to teach an antibody with specificity to SEQ ID NO:1. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alexander Volkov whose telephone number is (571) 272-1899. The examiner can normally be reached M-F 9:00AM-5:00PM (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bao-Thuy Nguyen can be reached on (571) 272-0824. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form. /ALEXANDER ALEXANDROVIC VOLKOV/Examiner, Art Unit 1677 /REBECCA M GIERE/Primary Examiner, Art Unit 1677
Read full office action

Prosecution Timeline

Dec 14, 2023
Application Filed
Oct 01, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782361
IDENTIFICATION AND MONITORING OF ACID HYDROLYSIS PRODUCTS OF IMMUNOGLOBULIN HEAVY CHAINS
6y 7m to grant Granted Nov 03, 2026
Patent 12768842
MASS SPECTROMETRY CONTROLS
3y 11m to grant Granted Oct 20, 2026
Patent 12742786
ASSAY AND KIT FOR LIVE ANTIGEN DETECTION AND MONITORING OF NEUROCYSTICERCOSIS
3y 12m to grant Granted Sep 22, 2026
Patent 12669512
PROTEIN DIAGNOSTIC BIOMARKER FOR SEVERE DRUG ERUPTION
3y 5m to grant Granted Jun 30, 2026
Patent 12656339
METHODS, REAGENTS, AND SUBSTRATES FOR DETECTING TARGET ANALYTES
5y 3m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
30%
Grant Probability
51%
With Interview (+21.5%)
4y 0m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 95 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month